CoChat
Sign Up
Cited by 50Probiotics and Fermented FoodsInflammatory Bowel DiseaseGut microbiota and health

Effects of Exopolysaccharide-Producing Probiotic Strains on Experimental Colitis in Rats

Şengül, Neriman, Aslím, Belma, Uçar, Gülberk, Yücel, Nihal, Işk, Sevil, Bozkurt, Hatice, Sakaoğullarí, Zişan, Atalay, Fuat·2006·Diseases of the Colon & Rectum
DOI 10.1007/s10350-005-0267-6
Open this paper in CoChat — free account

Abstract

PURPOSE: Inflammatory bowel disease is suggested to result from a dysregulated immune response toward intestinal microflora, which may be restored by probiotic therapy based on the concept of healthy microflora. Ideal probiotic bacteria may be beneficial in inflammatory bowel disease; however, the mechanism of action and the clinical efficacy of probiotic usage are still unclear. In the present study, the effect of exopolysaccharide producing probiotics was evaluated on an experimental colitis model in rats. METHODS: Colitis was induced by intracolonic administration of acetic acid. Then, rats were treated daily with two probiotic strains, Lactobacillus delbrueckii subsp. bulgaricus B3 strain (exopolysaccharide of 211 mg/l: high-EPS group) or Lactobacillus delbrueckii subsp. bulgaricus A13 strain (EPS of 27 mg/l: low-EPS group), which were given into the stomach. The non-colitis-fed control group was only treated with high-exopolysaccharide strain. The model-control and control groups were treated only with tap water. Rats were killed after a seven-day treatment period. Disease activity was quantified by use of histologic scores and colonic myeloperoxidase activity, which is a marker of neutrophil infiltration during inflammation. RESULTS: The enhanced inflammatory response was accompanied by a higher level of myeloperoxidase activity in the colitis group. Histologic scores of colonic damage and myeloperoxidase activity were lower in both probiotic-treated groups compared with those of the colitis control group (P<0.001), although the mentioned scores improved significantly more in the high-EPS group than in the low-EPS group (P<0.001). CONCLUSIONS: Exopolysaccharide-producing probiotics significantly attenuate experimental colitis, which may be mediated by exopolysaccharide in a dose-dependent manner. Therefore, exopolysaccharide-producing probiotics may be a promising therapeutic role in inflammatory bowel disease.

Integrity signals

Registry

Crossref · 10.1007/s10350-005-0267-6

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A high EPS-producing Lb. delbrueckii ssp. bulgaricus B3 strain exhibited higher antioxidant and metal ion chelating activities than Lb. delbrueckii ssp. bulgaricus A13, a low EPS-producing strain.

    “A study carried out by Sengül et al. [118] reported that a high EPS-producing Lb. delbrueckii ssp. bulgaricus B3 strain exhibited higher antioxidant and metal ion chelating activities than Lb. delbrueckii ssp. bulgaricus A13, a low EPS-producing strain.”

    From Lactic Acid Bacteria Exopolysaccharides Producers: A Sustainable Tool for Functional Foods (2021) · cites this paper as [118]

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Şengül, N., Aslím, B., Uçar, G., Yücel, N., Işk, S., Bozkurt, H., Sakaoğullarí, Z., & Atalay, F.
Affiliations
  • Türkiye Yüksek İhtisas Hastanesi (TR)
  • Hacettepe University (TR)
  • Gazi University (TR)
ORCID
Venue
Diseases of the Colon & Rectum
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-02
Volume
49
Issue
2
Pages
250-258
ISSN
0012-3706 (ISSN-L)
DOI
10.1007/s10350-005-0267-6
OpenAlex
W1988289363
Cited by
50
References
51
Citations by year
2024: 3 · 2023: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
FWCI
1.68
Type
journal article
Language
en
Open access
closed
Locations
  • Diseases of the Colon & Rectum (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Lactobacillus bulgaricus, experimental colitis, acetic acid-induced colitis, inflammatory bowel disease, myeloperoxidase activity, neutrophil infiltration, dose-dependent effects, colonic inflammation, probiotic therapy
MeSH terms
Animals, Colitis, Colon, Disease Models, Animal, Female, Intestinal Mucosa, Irritants, Polysaccharides, Bacterial, Rats, Sprague-Dawley, Acetic Acid, Probiotics, Lactobacillus delbrueckii, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review